Amgen Will Use Partnerships and M&A to Enter China Market
by Richard Daverman, PhD
February 14, 2013 -- Amgen is planning a China marketing initiative, using a combination of partnerships and M&A to gain a foothold. It expects to have its own patented drugs on the China market by 2015. At the same time, the company has announced it will establish a biosimilar capability that will produce versions of its competitors’ biologic drugs. To make these drugs, Amgen is currently building a plant in Singapore, which will be completed by 2017. The company expects to generate $1 billion of revenues from biosimilars in emerging market countries. More details....
Stock Symbol: (NSDQ: AMGN)